Phase 3 Readout
RVMD: Phase 3 Topline: RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus
December 1, 2027 · daraxonrasib. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2027
- Company
- REVOLUTION MEDICINES, INC. (RVMD)
- Drug
- daraxonrasib
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus
- Drug
- daraxonrasib
- Indication
- PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; PDAC